2Honkanen V E, MeCrindle B W, Laxer R M, et al. Clinical relevance of the risk factory for coronary artery inflammation in Kawasaki disease [ J ]. Pediatr Cardiol, 2003, 24 ( 2 ) : 122.
3Gundogda F, Bozkurt E, Kizihune A, et al. The effect of betablocker (carvedilol) therapy on N - terminal por- brain natriuertic peptid levels and eehocardiographie findings in patients with eongestiveheart failure [ J ]. Echocardiography, 2007, 24(2): 113.
4Kawamura T, Wago M, Kawaguchi H, et al. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease[J]. Pediatr Int, 2000, 42: 241.
5Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnistie guidelines for Kawasaki disease(the 5th revised edtion)[J]. pediatr Int, 2005, 47:232.
6吴瑞萍,胡亚关,江载芳.实用儿科学[M].人民卫生出版社,2002:687.
7Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome [J]. N Engl J Med, 1991, 324 ( 23 ) : 1633,-1639.
8Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease ( the 5th revised edition ) [J]. Pediatr Int, 2005, 47 ( 2 ) : 232-234.
9Furusho K, Sato K, Soeda T, et al. High-dose intravenous gamma-globulin for Kawasaki disease [J]. Lancet, 1984, 2: 1055 - 1058.
10Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responseness to intravenous high-dose gamma- globulin therapy in patients with Kawasaki disease at onset [J]. J Pediatr, 2000, 137 ( 2 ) : 172-176.
